Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 12/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 7/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.44 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464909 | 0.86 | GRIK1 (0.31) | SLC7A5GRIK1GRIK2 | |
| SCHEMBL29291859 | 0.84 | SLC1A1 (0.42) | SLC7A5GRIK1GRIK2GRIA4GRIK3 | |
| SCHEMBL9701317 | 0.83 | GRIK1 (0.45) | SLC7A5GRIK1GRIK2GRIA4GRIK3 | |
| SCHEMBL17222477 | 0.83 | GRIK1 (0.45) | SLC7A5GRIK1GRIK2GRIA4GRIK3 | |
| SCHEMBL28242874 | 0.83 | SLC7A5 (0.44) | SLC7A5GRIK1GRIK2GRIA4GRIK3 | |
| SCHEMBL8439242 | 0.83 | SLC7A5 (0.44) | SLC7A5GRIK1GRIK2GRIA4GRIK3 | |
| SCHEMBL16972731 | 0.83 | SLC7A5 (0.64) | SLC7A5GRIK1GRIK2GRIA4GRIK3 | |
| SCHEMBL21682803 | 0.82 | SLC7A5 (0.47) | SLC7A5GRIK1GRIK2GRIA4GRIK3 | |
| SCHEMBL1444867 | 0.81 | SLC1A1 (0.50) | SLC7A5GRIK1GRIK2GRIA4GRIK3 | |
| SCHEMBL5165368 | 0.80 | GRIK1 (0.42) | SLC7A5GRIK1GRIK2GRIA4GRIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101918834-A | Calibrator/control for simultaneous assay of proteins capable of complexing with one another | ORTHO CLINICAL DIAGNOSTICS INC | 2010-12-15 | — | — | CN | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| EP-0210257-A4 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS. | HURWITZ CHARLES (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0210257-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ, Charles (US) | 1987-02-04 | — | — | EP | claimed |
| WO-1986004588-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ CHARLES (US) | 1986-08-14 | — | — | WO | claimed |
| CN-110291196-A | Thermostable reverse transcriptase mutants | 宝生物工程株式会社 | 2019-09-27 | — | — | CN | disclosed |
| CN-107108729-A | Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies, and uses thereof | 中外制药株式会社 | 2017-08-29 | — | — | CN | disclosed |
| CN-103038258-B | Compositions and methods of use for antibodies to treat low density lipoprotein-related protein 6(LRP6) | 诺华股份有限公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-3102611-A1 | HUMANIZED BETA-AMYLOID BINDING MOLECULES AND USES THEREOF | Cangene Corporation (CA) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015113169-A1 | HUMANIZED BETA-AMYLOID BINDING MOLECULES AND USES THEREOF | CNJ HOLDINGS, INC. (CA) | 2015-08-06 | — | — | WO | disclosed |
| CN-101918834-A | Calibrator/control for simultaneous assay of proteins capable of complexing with one another | ORTHO CLINICAL DIAGNOSTICS INC | 2010-12-15 | — | — | CN | disclosed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | disclosed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | disclosed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | disclosed |
| EP-0781295-A4 | ASP B1 INSULIN ANALOGS | LILLY CO ELI (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-0781295-A1 | ASP B1 INSULIN ANALOGS | ELI LILLY AND COMPANY (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996004307-A1 | ASPB1 INSULIN ANALOGS | ELI LILLY AND COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| US-4772480-A | Method of controllingly aging edible material | YAMANE AKIYOSHI (JP) | 1988-09-20 | — | — | US | disclosed |